Time course of optical coherence tomography and fundus findings in a representative non-recurrent eye. by Yasuyuki Sotani (20114144)

Annual treatment frequencies in all eyes. by Yasuyuki Sotani (20114144)

“…<p>The number of anti-VEGF treatments, STTA, MA-PC, PPV, and total treatments (mean ± SD) significantly decreased from 2.6 ± 1.6, 0.3 ± 0.8, 0.6 ± 0.8, 0.1 ± 0.3, and 3.7 ± 1.7 preoperatively to 0.8 ± 1.9, 0.0 ± 0.2, 0.3 ± 1.0, 0.0, and 1.2 ± 2.2; at year 2 to 0.7 ± 2.0, 0.1 ± 0.6, 0.0 ± 0.2, 0.0 ± 0.2, and 1.0 ± 2.1; and at year 3 to 0.9 ± 2.2, 0.0, 0.2 ± 1.0, 0.0 ± 0.2, and 1.1 ± 3.1 (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual number of outpatient visits in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

Time course of central retinal thickness (CRT) in all eyes. by Yasuyuki Sotani (20114144)

“…<p>Mean CRT (μm ± standard deviation) significantly decreased from 504.7 ± 118.2 μm preoperatively to 302.5 ± 60.5 at 1 month, 307.5 ± 64.4 at 3 months, 286.8 ± 49.0 at 6 months, 305.3 ± 79.5 at 12 months, 288.8 ± 79.1 at 24 months, and 295.2 ± 87.4 at 36 months (Kruskal–Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Time course of central retinal thickness (CRT) in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…<p>In the recurrence group, CRT (μm ± standard deviation) significantly decreased from 546.1 ± 117.0 μm preoperatively to 317.1 ± 46.9, 317.8 ± 55.6, 290.8 ± 33.5, 342.9 ± 82.2, 333.0 ± 84.2, and 349.8 ± 76.9 μm at 1, 3, 6, 12, 24, and 36 months, respectively (Kruskal-Wallis test, P < 0.001; Dunn’s test, **P < 0.01). …”

Annual treatment frequencies in recurrence and non-recurrence groups. by Yasuyuki Sotani (20114144)

“…These significantly decreased to 2.3 ± 2.6, 0.1 ± 0.3, 0.8 ± 1.6, 0.0, and 3.1 ± 2.8 in the first year; 2.1 ± 2.8, 0.4 ± 1.0, 0, 0.1 ± 0.3, and 2.6 ± 2.8 in the second year; and 2.0 ± 2.2, 0, 0.6 ± 1.7, 0.1 ± 0.3, and 2.8 ± 3.5 in the third year (Kruskal–Wallis test, p < 0.001; Dunn’s test, *P < 0.05, **P < 0.01). …”

Geometric mean anti-<i>Na</i>-GST-1 IgG subclass levels over time. by David J. Diemert (8135568)

Subjects:

Metformin lotion is anti-inflammatory in serum following skin wounds. by Jianying Zhang (256508)

PRV UL4 augments ASC oligomerization and speck formation. by Xiaohua Zhang (350570)

PRV UL4 interacts with ASC. by Xiaohua Zhang (350570)

Anti-<i>Na</i>-GST-1 IgG antibody levels and seroresponse rates by vaccine group and study day. by David J. Diemert (8135568)

Subjects:

Supplementary data. by Malte Ostendarp (13217973)

“…In contrast, the addition of hydrogen at 26 °C caused a significant decrease in the photophysiology of both <i>Acropora</i> sp. and <i>P. verrucosa</i>. …”

Flow diagram showing number of subjects included in the study population. by Jung-Tae Kim (8997767)

Mod antibody and RNAi validations. by Amalia S. Parra (4173004)

Mod loss is associated with a reduction of central brain NBs. by Amalia S. Parra (4173004)

Geometric mean anti-<i>Na</i>-GST-1 IgG levels over time by vaccine group, as measured by ELISA (Arbitrary Units). by David J. Diemert (8135568)

Subjects:

Inactivation of MnuA and 5′-NT reduced bacterial fitness and virulence of <i>M</i>. <i>bovis</i> PG45 in mammary glands. by Aga E. Gelgie (17661720)

Details of the GWAS data in this study. by Jing Wang (6206297)

“…</p><p>Results</p><p>This study shows that increases of anti-H. pylori IgG seropositivity was significantly associated with an increased risk of CHD (OR=1.003, 95% CI:1.0001.006, P = 0.048) and increases in peak insulin response (β = 0.214, 95% CI: 0.025–0.403, P = 0.026), decrease in total free cholesterol levels (β = ‒0.031, 95% CI: ‒0.061 to ‒0.000, P = 0.045), decreased waist circumference (β = ‒0.073, 95% CI: ‒0.138 to ‒0.008, P = 0.027) and waist-to-hip ratio (β = ‒0.069, 95% CI: ‒0.136 to ‒0.002, P = 0.044). …”

Receiver operating characteristic curve for anti-NIE antibodies for <i>S. stercoralis.</i> by Jannet A. Tobon Ramos (20855642)

RipE1 phosphorylation and NbUCH-mediated deubiquitination are independent mechanisms leading to RipE1 stability. by Wenjia Yu (9422059)